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This single center, retrospective study adds some important
caveats to the scant clinical knowledge relating to the approach of
patients with carotid body tumors (CBT) or paragangliomas.
CBTs are known to occur in either sporadic or familial cases, the
latter resulting from a mutation of the succinate dehydrogenase
gene with a greater phenotypic penetration when altitude or
hypoxia is present.1 In patients with CBT, it has therefore been
customary to empirically recommend the careful evaluation for
multifocal disease and screen patient families to identify latenthas provided clear evidence to support the benefit of this
practice.
Though the patients in this study were not genetically evalu-
ated, the data nicely elucidate the relevance of a field defect in the
glomus cells of the paragangliomas. The identification in the study
of concurrent vagal paragangliomas (15%) or concurrent bilateral
CBT (21%) emphasizes the synchronous nature of the disease, and
the importance of bilateral neck evaluation withDuplex ultrasound
or contrast computed tomography. However, this study took this
a step further with careful evaluation of the proband’s family
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in their patient population was 28%, and this screening process of
the patient families yielded an additional 16 tumors and two new
family groups of inherited predilection to CBT. In addition, the
authors provided strong evidence for lifetime patient follow-up,
identifying two recurrent CBT and a new metachronous paragan-
glioma in 12% of patients (Table IV).
As in prior reports, this study shares the Achilles heel of CBT
surgical resection, a high incidence of cranial nerve injury (22%). As
they report this complication of cranial nerve injury to be signifi-
cantly higher with larger CBT surgery (4.6 cm vs 3.1 cm diameter),
early surgery is recommended by the authors while tumors are
small. It would follow that screening of high-risk populations to
identify smaller tumors for resection should lower this incidence of
cranial nerve injury. However, other methods, though unproven,
should be considered with large CBT and may help lower the possi-
bility of cranial nerve injury. These include preoperative catheter-
based embolization, which has been shown to have less operative
bleeding and facilitate the surgery, and a multidisciplinary ap-
proach with head and neck surgeons identifying and dissecting thenerves off the CBT while the vascular surgeons dissect the often
densely adherent tumors off the carotid artery and undertake
vascular reconstructions as needed.2
Though the dilemma of how best to minimize cranial nerve
injury has not been resolved, the incidence of CBT is so low that
randomized controlled studies are unlikely to be undertaken. Early
detection with careful screening and follow-up of high-risk pa-
tients, especially those with bilateral or familial CBTs as advocated
in this study, may identify smaller CBT. Until there are more data,
identifying and operating on these smaller tumors is the only
approach available to yield a lower complication rate of cranial
nerve injury.
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